- Presentations to be webcast on www.exelixis.com
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 20, 2018--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the following investor conferences in
The 30th Annual Piper Jaffray Healthcare
Conference: Exelixis is scheduled to present at 11:00 AM EST / 8:00 AM
PST on Tuesday, November 27, 2018 in New York.
Evercore ISI HealthConX: Exelixis is scheduled to present at 2:00 PM
EST / 11:00 AM PST on Wednesday, November 28, 2018 in Boston.
To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the Investors &
Media heading. Please connect to the company’s website at least 15
minutes prior to each presentation to ensure adequate time for any
software download that may be required to listen to the webcasts.
Replays will also be available at the same location for 14 days.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our three
commercially available products, CABOMETYX® (cabozantinib),
COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib),
and have entered into partnerships with leading pharmaceutical companies
to bring these important medicines to patients worldwide. Supported by
revenues from our marketed products and collaborations, we are committed
to prudently reinvesting in our business to maximize the potential of
our pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug discovery –
all to deliver the next generation of Exelixis medicines and help
patients recover stronger and live longer. Exelixis is a member of
Standard & Poor’s (S&P) MidCap 400 index, which measures the performance
of profitable mid-sized companies. For the second consecutive year,
Exelixis earned a spot on Deloitte’s Technology Fast 500 list, a yearly
award program honoring the 500 fastest-growing companies over the past
four years. For more information about Exelixis, please visit www.exelixis.com,
on Twitter or like ExelixisInc
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005565/en/
Source: Exelixis, Inc.
For Exelixis, Inc.